CD4 and AIDS: In other words, even patients traditionally considered at higher risk for viremia events, such as those older in age, with a history of AIDS, or with high baseline viral load or low CD4 counts, did not show a disproportionate increase in blips on two-drug therapy compared with three-drug therapy.